Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NACompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

May 1, 2018

Primary Completion Date

March 1, 2019

Study Completion Date

August 15, 2019

Conditions
Ocular Surface DiseaseGlaucoma, Open-Angle
Interventions
DEVICE

iStent or iStent inject implantation with concomitant cataract surgery

Standard phacoemulsification cataract surgery followed by ab interno implantation of either iStent or iStent inject trabecular micro-bypass stent(s). Preoperatively and at specified visits through 3 months postoperative, patients will complete evaluations of their ocular surface disease (specifically OSDI score, hyperemia, corneal/conjunctival staining, and tear break-up time).

Trial Locations (1)

57108

Vance Thompson Vision, Sioux Falls

All Listed Sponsors
lead

Vance Thompson Vision

OTHER

NCT04452279 - Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification | Biotech Hunter | Biotech Hunter